Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.

Gaetano FacchiniSabrina RossettiMassimiliano BerrettaCarla CavaliereSarah ScagliariniMaria Giuseppa VitaleChiara CiccareseGiuseppe Di LorenzoErica PalesandroVincenza ConteducaUmberto BassoEmanuele NaglieriAzzurra FarnesiMichele AietaNicolò BorsellinoLeonardo La TorreGelsomina IovaneLucia BonomiDonatello GasparroEnrico RicevutoMichele De TursiRocco De VivoGiovanni Lo ReFrancesco GrillonePaolo MarchettiFerdinando De VitaClaudio ScavelliClaudio SiniSalvatore PiscontiAnna CrispoVittorio GebbiaAntonio MaestriLuca GalliUgo De GiorgiRoberto IacovelliCarlo BuonerbaGiacomo CartenìCarmine D'Aniello

Published in: Journal of translational medicine (2019)

Axitinib was effective and safe in a not selected real life mRCC population. Trial registration INT - Napoli - 11/16 oss. Registered 20 April 2016. http://www.istitutotumori.na.it.

Keyphrases

metastatic renal cell carcinoma
squamous cell carcinoma
small cell lung cancer
papillary thyroid
cell therapy
study protocol
single cell
clinical trial
phase iii
squamous cell
stem cells
randomized controlled trial
mesenchymal stem cells
bone marrow
double blind